Ohsu Knight Cancer Institute
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 240
- Registration Number
- NCT00324324
- Locations
- 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00321698
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Portland, Portland, Oregon, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 33
- Registration Number
- NCT00303849
- Locations
- 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 81
- Registration Number
- NCT00293475
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
- Conditions
- Interventions
- Biological: filgrastimBiological: anti-thymocyte globulinDrug: cyclophosphamideDrug: busulfanDrug: carmustineDrug: cyclosporineDrug: fludarabine phosphateDrug: methotrexateDrug: cytarabineDrug: mycophenolate mofetilDrug: etoposideDrug: methylprednisoloneDrug: tacrolimusDrug: melphalanProcedure: peripheral blood stem cell transplantationRadiation: radiation therapyProcedure: umbilical cord blood transplantation
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 200
- Registration Number
- NCT00281879
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT00258440
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00253513
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 4
- Registration Number
- NCT00253552
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 89
- Registration Number
- NCT00253643
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Kaiser Permanente Center for Health Research, Portland, Oregon, United States
🇺🇸Veterans Affairs Medical Center - Portland, Portland, Oregon, United States
Melphalan With BBBD in Treating Patients With Brain Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00253721
- Locations
- 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States